Clinical Response to Azacitidine in Myelodysplastic Neoplasms is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor cells *in vivo*

Running title: *Azacitidine response in MDS*

Julie A.I. Thoms^{1*}, Feng Yan², Henry R. Hampton¹, Sarah Davidson^{3,4}, Swapna Joshi⁵, Jesslyn Saw⁶, Chowdhury H. Sarowar⁵, Xin Ying Lim⁵, Andrea C. Nunez⁵, Purvi M. Kakadia⁷, Golam Sarower Bhuyan⁵, Xiaoheng Zou¹, Mary Nguyen¹, Elaheh S. Ghodousi¹, Forrest C. Koch⁸, Fatemeh Vafaee 8,9 , Russell Pickford¹⁰, Mark J. Raftery¹⁰, Sally Hough³, Griselda Buckland^{3,4}, Michelle Bailey³, Yuvaraj Ghodke^{3,4}, Noorul Absar³, Lachlin Vaughan^{5,11,12}, Leonardo Pasalic^{11,12}, Chun Y. Fong¹³, Melita Kenealy¹⁴, Devendra K. Hiwase¹⁵, Rohanna I. Stoddart¹⁶, Soma Mohammed¹², Linda Lee¹⁷, Freda H. Passam^{18,19}, Stephen R. Larsen¹⁹, Kevin J. Spring^{20,21}, Kristen K. Skarratt²², Patricia Rebeiro²³, Peter Presgrave²⁴, William S. Stevenson¹⁷, Silvia Ling²⁵, Campbell Tiley²⁶, Stephen J. Fuller²², Fernando Roncolato²⁷, Anoop K. Enjeti^{28,} ^{29, 30}, Dirk Hoenemann³¹, Charlotte Lemech³², Christopher J. Jolly¹, Stefan K. Bohlander⁷, David J. Curtis⁶, Jason W H Wong³³, Ashwin Unnikrishnan⁵, Mark Hertzberg³⁴, Jake Olivier³⁵, Mark N. Polizzotto^{3,4*} and John E. Pimanda^{1,5,34*}

¹School of Biomedical Sciences, University of New South Wales, Sydney, Australia; ²Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, VIC, Australia; ³Kirby Institute, University of New South Wales, Sydney, Australia; ⁴ANU *Clinical Hub for Interventional Research (CHOIR), John Curtin School of Medical Research, Canberra, Australia; 5School* of Clinical Medicine, University of New South Wales, Sydney, Australia: ⁶Australian Centre for Blood Diseases, Monash *University, Melbourne, Victoria, Australia ; 7 Leukaemia & Blood Cancer Research Unit, Department of Molecular Medicine* and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand; ⁸School of *Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia; 9UNSW Data Science Hub, University of New South Wales, Sydney, Australia; 10Bioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, Australia; 11Westmead Hospital, Sydney, Australia; 12ICPMR, Department of Haematology, Westmead Hospital, Sydney, Australia; 13Department of Haematology, Austin Health, Melbourne, Australia; 14Cabrini Hospital, Melbourne, Australia; 15Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia; 16University of New South Wales, Sydney, Australia; 17Royal North Shore Hospital, Sydney, Australia; 18Haematology Research Group, Heart Research Institute, Sydney, NSW, Australia; 19Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW,* Australia; ²⁰Medical Oncology Group, Liverpool Clinical School, School of Medicine, Western Sydney University and Ingham *Institute for Applied Medical Research, Liverpool, NSW, Australia; 21South-West Sydney Clinical Campuses, UNSW Medicine & Health, Sydney, NSW, Australia.; 22Sydney Medical School, Nepean Clinical School, Faculty of Medicine and Health, University of Sydney, Nepean Hospital, Kingswood, NSW 2747, Australia; 23Blacktown Hospital, Sydney, Australia; 24Wollongong Hospital, Wollongong, Australia; 25Liverpool Hospital, Sydney, Australia; 26Central Coast Health, Gosford Hospital, Gosford, Australia; 27St. George Hospital, Sydney, Australia; 28Department of Haematology, Calvary Mater Hospital, Waratah, NSW, Australia; 29University of Newcastle Callaghan Australia and Precision Medicine Program; 30Hunter Cancer Research Institute, New Lambton Heights, Australia ; 31Otway Pharmaceutical Development and Consulting* Pty Ltd, Forrest, Australia; ³²Scientia Clinical Research, Medical Oncology, Prince of Wales Hospital, Sydney, Australia; *33School of Biomedical Sciences, The University of Hong Kong, Hong Kong SAR, China; 34Department of Clinical* Haematology, Prince of Wales Hospital, Sydney, Australia; ³⁵School of Mathematics and Statistics, University of New South *Wales, Sydney, Australia.*

*Correspondence: John Pimanda; [jpimanda@unsw.edu.au,](mailto:jpimanda@unsw.edu.au) Julie Thoms; [j.thoms@unsw.edu.au,](mailto:j.thoms@unsw.edu.au) Mark Polizzotto; mark.polizzotto@anu.edu.au

Word count (abstract): 150, Word count (text): 4611, Figure count: 6 main, 4 supplemental, Table count: 7 supplemental, Reference count: 70.

Keywords: myelodysplastic syndromes, chronic myelomonocytic leukaemia, acute myeloid leukaemia, hypomethylating agents, azacitidine therapy, haematopoietic stem cell, DNA methylation
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Hypomethylating agents are used as frontline therapy for myelodysplastic neoplasms (MDS), but clinical response is unpredictable. To determine whether response was associated with *in vivo* dynamics of DNA hypomethylation, we conducted a phase 2 trial for MDS using both injection and oral azacitidine (AZA). We established that global DNA methylation levels in peripheral blood and bone marrow mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, there were distinct baseline and early drug induced differences in CpG methylation in haematopoietic stem and progenitor cells (HSPCs) in responders compared to non-responders that overlapped with regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. Following six cycles of therapy when clinical response typically manifests, differential hypomethylation in responder HSPCs pointed to marrow adaptation as a driver of enhanced haematopoiesis. Taken together, CpG methylation differences in HSPCs may explain variable response to AZA.

Introduction

Myelodysplastic neoplasms (MDS) and chronic myelomonocytic leukemia (CMML) are clonal malignancies driven by accumulation of somatic mutations in haematopoietic stem cells (HSCs) which lead to impaired haematopoiesis and cytopenias along with increased likelihood of progressing to AML 1-6. High risk patients who are ineligible for haematopoietic stem cell transplant are treated with hypomethylating agents (HMAs), including azacitidine (AZA), which in a subset of patients leads to improved peripheral cell counts and delayed progression to AML $^{7-10}$. In the context of MDS/CMML, AZA has generally been administered by subcutaneous injection (Vidaza®, $75mg/m^2$ /day), with a treatment cycle consisting of 7 days of injections followed by 21 days rest. More recently, an oral formulation (CC-486/Onureg®, 300mg/day for 14 days followed by 14 days rest) has been approved for maintenance therapy in AML patients who have achieved complete or incomplete remission following induction therapy and are not proceeding to a stem cell transplant $¹¹$. Clinical response to HMAs is</sup> generally not apparent until after 4-6 treatment cycles 7 , and for patients with primary or secondary resistance to HMAs, treatment options are limited to enrolment in relevant clinical trials or supportive care.

Hypomethylating agents such as AZA and decitabine (DAC) are nucleoside analogues that, following intracellular conversion processes $12,13$, are incorporated into DNA and, in the case of AZA, into RNA 14. HMA incorporation into DNA requires that target cells are cycling 15 , and we have previously reported a correlation between cell cycle parameters at diagnosis and subsequent patient response ¹⁶. Once incorporated into DNA, HMAs trap the maintenance DNA methyltransferase DNMT1 leading to formation of DNA-protein adducts, degradation and cellular depletion of DNMT1, and subsequent global hypomethylation $17-20$. Multiple stemcell-intrinsic effects of HMAs observed in patients have been proposed to mediate the clinical effects of HMAs including epigenetic reactivation of tumour suppressor genes $2^{1,22}$, activation

of silenced retroviral elements and subsequent viral mimicry response $^{23-25}$, DNA-damage response and related cytotoxicity $17,18,26$, induction of apoptosis $27-29$, and RNA-dependent mechanisms 30,13,31,32. However, HMA-mediated cytotoxicity is not essential for clinical response 33,34, and there is emerging evidence that response to HMAs (in the context of MDS/CMML) does not require complete eradication of mutated clones; rather that improved peripheral blood counts are driven by increased output from mutated stem cells 35,36,16,37. Overall, no straightforward relationship has been demonstrated between stem-cell-intrinsic effects of HMA treatment and patient outcome ^{21,38,39,16,40,41}, rendering prediction of response status and development of rationally designed combination therapies an ongoing challenge.

In particular, the association between HMA incorporation and DNA hypomethylation, and the clinical efficacy of these drugs is unclear. In a small retrospective study, HMA incorporation in a single initial treatment cycle tracked with global demethylation, with more variable uptake and hypomethylation observed in patients who did not subsequently respond ⁴¹. However, HMA incorporation and DNA hypomethylation kinetics have not previously been studied over the time span where clinical response becomes evident. Furthermore, these parameters have not been assessed in parallel with cell cycle characteristics or changes in clonal composition during HMA treatment. To address these relationships, we prospectively collected bone marrow (BM) and peripheral blood (PB) as part of a phase II clinical trial (NCT03493646) designed to evaluate *in vivo* AZA incorporation in mononuclear cells following treatment with Vidaza (injection AZA) or CC-486 (oral AZA). The primary objective of the trial was to assess drug incorporation into DNA and global changes in DNA methylation using an LC-MS/MS based method 41, while secondary objectives included observation of cell cycle changes in haematopoietic stem and progenitor cells (HSPCs), tracking of clonal variants, and assessment of any relationship between these measures and clinical response.

Results

Patient cohort and clinical outcomes

Patients newly diagnosed with high risk (HR) MDS, CMML, or low blast AML, and ineligible for allogeneic stem cell transplant or intensive chemotherapy (Table S1), were enrolled to an open label phase 2 multicentre investigator-initiated trial (NCT03493646) and administered six cycles of injection AZA followed by six cycles of oral AZA (Figure 1A). Clinical response was assessed following cycle 6 (C6D28) and cycle 12 (C12D28) using IWG2006 criteria ⁴². Forty patients commenced treatment. Of the 24 who completed 6 cycles of injection AZA, there were 16 responders (seven complete remission (CR), three marrow complete response (mCR), and six hematological improvement (HI)) and eight non-responders (five stable disease (SD), three progressive disease (PD)/failures) (Figure 1B, Figure 1C, Table S2). All participants were retrospectively assessed using IWG2023 criteria 43; of these, one patient (P10) changed from non-responder to responder at C12D28 (Table S3).

Twenty-two patients entered the oral AZA phase and completed median 2 cycles (range 0-6); a total of 100 cycles of oral AZA were delivered. Reasons for discontinuation during the oral AZA phase (n=11) included disease progression (five patients, 46%), unacceptable toxicity (three patients, 27%; one haematological, two gastrointestinal), changes in goals of care (two patients, 18%), and intercurrent medical complication (one patient, 9%). The most common adverse events during oral AZA therapy were haematological (Table S4, Table S5): 23 cycles in 13 patients were complicated by grade 4 neutropenia, one cycle in one patient by febrile neutropenia, and 14 cycles in 10 patients by grade 4 thrombocytopenia. Other adverse events were less common, with 13 cycles in nine patients complicated by grade 3 gastrointestinal toxicity (diarrhoea; five events in three participants, nausea; four events in three

participants, rectal haemorrhage; two events in one participant, one event each for vomiting and abdominal pain; no grade 4 adverse events were observed).

11/22 patients who commenced oral AZA reached the second response assessment (C12D28) comprising seven responders (two CR, four mCR, one HI) and four non-responders (two SD, one PD, one relapse after CR/PR). The seven responders at C12D28 included five responders and two non-responders at C6D28 (i.e. two patients who showed a delayed clinical response), while the four non-responders at C12D28 had previously shown response at C6D28 (Figure 1C). Most patients completing cycle 12 elected to continue to receive treatment with oral AZA (64%, 7/11).

Cell cycle parameters at diagnosis and over the course of treatment do not correlate directly with clinical outcome

Previous studies suggested that patients who respond to AZA have a higher proportion of actively cycling $(S/G₂/M)$ phase) $CD34⁺CD38^{hi}$ hematopoietic progenitor cells (HPC) at baseline compared to patients who do not have a clinical response 16 . We measured cell cycle parameters in bone marrow CD34⁺CD38^{lo} HSC and HPC across the course of AZA treatment (Figure 2A). In HSCs, there were few actively cycling cells at baseline regardless of subsequent clinical response (median % in cell cycle phase, [interquartile range]; Responders (R): [0.5, $(0.1-1.2)$]; Non-responders (NR): [0.2, (0.1-0.5)]), and the overall proportion of cells in G₀ or G₁ were similar between response groups (Figure 2Bi,ii,iii, *left panels*; G₀ - R: [83.2, (68.7-90.7)]; NR: [57.7, (48.6-91.4)]; G1 - R: [16.6, (6.3-25.6)]; NR: [35.3, (7.4-44.6)]). Following six cycles of injection AZA the proportion of HSCs in $S/G_2/M$ was relatively stable (R: [0.5, $(0.0-0.9)$]; NR: [1.2, $(0.6-1.4)$]). There was an overall decrease in the proportion of quiescent G0 cells (R: [53.8, (47.2-60.8)]; NR: [56.8, (44.6-61.2)]) and concomitant increase in the proportion of cells in G1 (R: [42.6, (37.5-48.5)]; NR: [40.9, (35.0-53.4)]), but this difference reached significance only in responders (Figure 2Bi,ii,iii, *right panels*). In HPCs, there was a trend for responder patients to have an increased proportion of cells in S/G2/M at baseline (R: $[5.0, (2.9-5.7)]$; NR: $[3.2, (2.2-6.0)]$, although this did not reach statistical significance. Similar to HSCs, the overall proportion of G_0 and G_1 cells were similar between response groups at baseline (Figure 2Ci,ii,iii; G₀ - R: [59.9, (55.8-69.8)]; NR: [48.4, (29.8-71.2)]; G₁ - R: [32.9, (25.0-38.6)]; NR: [48.5, (24.0-61.5)]. After six treatment cycles, some patients had shifts in the proportion of HPCs in $S/G_2/M$, but there was no consistent change either across the entire cohort, or within response groups (R: [7.2, (4.1-9.9)]; NR: [7.3, (5.7-9.2)]). However, similar to HSCs there was an overall decrease in the proportion of quiescent cells $(G_0 - R: [23.5, (17.3-$ 38.7)]; NR: [35.2, (24.2-40.4)]) and an increase in the proportion of G₁ cells (R: [69.4, (56.4-72.8)]; NR: [57.5, (54.4-66.1)]) both of which were significant only in responders (Figure 2Ci,ii,iii, *right panels*).

At the start of the oral phase (C7D1), HSC cell cycle parameters were similar between responders and non-responders (Figure S1Ai,ii,iii; $S/G_2/M$ - R: [0.6, (0.3-1.1)]; NR: [0.7, (0.3-1.3)]; G₀ - R: [47.9, (38.5-58.5)]; NR: [53.8, (47.3-60.6)]; G₁ - R: [43.7, (39.4-59.4)]; NR: [43.2, $(37.1-51.5)$]). For some patients, the quantity of HSCs was too low $(50$ phenotypic HSCs) to reliably measure percentage of cells in each cell cycle phase, limiting analysis of paired samples. Cell cycle parameters in HPCs at the start of the oral phase were also similar between response groups (Figure S1Bi,ii,iii; S/G2/M - R: [5.4, (4.3-7.3)]; NR: [8.2, (4.2-9.9)]; G_0 - R: [21.6, (17.0-28.6)]; NR: [39.5, (17.4-41.1)], G_1 - R: [72.2, (67.1-73.6)]; NR: [57.8, (52.1-72.6)]). There was a trend for responder patients to have an increase, and non-responder patients have a decrease in the proportion of cells in S/G2/M over the oral phase; strikingly, by the end of treatment, HPCs in non-responder patients had essentially stopped cycling (Figure 2D, Figure S1C; R: [9.9, (7.8-13.4)]; NR: [2.5, (2.2-2.6)]).

Cell cycle kinetics might directly influence the amount of DAC incorporated into DNA, and therefore the extent of DNA demethylation. We compared cell cycle parameters with DAC incorporation and global DNA demethylation in circulating cells during cycle 1 in HSCs (Figure 2E) and HPCs (Figure 2F). Immediately following a single treatment cycle DAC incorporation and demethylation were observed in essentially all patients, and the degree of DAC incorporation was correlated to the proportion of HPCs in S/G2/M (Figure 2F; Spearman $r = 0.44$, $P = 0.03$). During cycle 7 (oral phase) DAC incorporation and demethylation were again observed in essentially all patients, however neither correlated with cell cycle parameters at this time point (Figure S1D, Figure S1E). Overall, we found that most patients had fewer quiescent cells following six cycles of AZA treatment, and at the end of cycle 12, HPCs in responder patients continued to cycle, while HPCs in non-responders had exited the cell cycle. However, cell cycle parameters did not directly correlate with clinical outcome.

DAC incorporation and global DNA demethylation in peripheral blood and bone marrow are not correlated with clinical response

AZA undergoes intracellular modification prior to being incorporated into newly synthesised DNA, where it traps the maintenance methyltransferase DNMT1 leading to DNMT1 degradation and DNA hypomethylation 19 (Figure 3A). We directly measured drug incorporation into DNA and relative global DNA methylation in PB mononuclear cells (MNCs) at 1-2 weekly intervals during both injection and oral treatment phases (Figure 1A). During the injection AZA phase, drug incorporation was higher in responders [0.093 (95% CI 0.066-0.120)] compared to non-responders $[0.045 (95\% \text{ CI } 0.011 - 0.079)]$ pmol DAC/ μ g DNA; $p = 0.032$ (Figure 3B). Analysis of drug incorporation at day 1 (D1), day 8 (D8) and day 22 (D22) revealed that incorporation differences were primarily driven by D8 measurements,

i.e. immediately following 7 days of AZA treatment (Figure 3B). However, overall differences in DNA methylation relative to baseline (100%) were comparable between responders [85.41% $(95\% \text{ CI } 77.40 - 93.43)$] and non-responders [86.85% (95% CI 76.69 – 97.01] (p= 0.83), with peak demethylation observed at D8 in both treatment groups (Figure 3C, Figure S2A-D).

Nineteen patients completed at least one cycle of oral AZA at 150 mg bid (i.e., completed C9) and were compared to all patients with injection AZA data ($n = 29$) for assessment of the primary outcome. Drug incorporation was higher during the injection phase (Figure 3D: injection AZA; 0.070 (95% CI 0.052 – 0.089) vs. oral AZA; 0.047 (95% CI 0.023 -0.070) pmol DAC/ μ g DNA, p = 0.02), again primarily driven by D8 measurements (Figure 3D). However, there was lower overall DNA methylation during the oral phase (Figure 3E: injection AZA; 86.42% (95% CI 81.06 – 91.78) vs. oral AZA; 77.64% (95% CI 71.67 – 83.61); p <0.0001). Methylation differences were significant at both D1 and D22, but not at D8 (Figure 3E). Thus, although we observed increased drug incorporation with injection AZA, there was greater and more sustained demethylation in response to oral administration of AZA.

During the oral phase, drug incorporation was comparable between responders and nonresponders (Figure 3F: responders; 0.059 (95% CI $0.012 - 0.106$) vs. non-responders; AZA 0.073 (95% CI 0.031 – 0.115) pmol DAC/ μ g DNA, p = 0.66). Similar to injection AZA, we did not observe any methylation differences between the response groups (Figure 3G: responders; 79.61% (95% CI 62.35 – 96.87) vs. non-responders; 79.23% (95% CI 64.31 – 94.15); $p = 0.97$).

Although DNA demethylation is a likely mediator of the therapeutic effects of AZA, in our cohort essentially every patient had reduced DNA methylation in peripheral blood in response to treatment, and there was no direct relationship between drug incorporation, level of global DNA demethylation, and clinical outcome (Figure 3C, Figure 3G). One possibility is that the clinically relevant demethylation events occur in specific cells within the bone marrow and may not be read out in circulating cells. We first measured global DNA demethylation in BM MNCs before and after AZA treatment in cycle 1 and cycle 7. Similar to PB, demethylation was apparent in BM MNC from the majority of patients and was not significantly different between responders and non-responders (Figure 3H).

MDS/CMML are diseases of stem cells, and clinical response in this cohort is measured in improved circulating blood counts likely driven by improved output from $CD34⁺$ HSPCs 36 . HSPCs are rare, and not amenable to AZA-MS analysis. However, relative methylation of LINE-1 promoters as a proxy measure of global methylation changes can be assessed in small cell numbers using a PCR-based assay 44 (Figure 3I, Figure S2E). Comparing CD34⁺ cells from responders and non-responders, there was a trend for greater demethylation in responders which reached statistical significance at C7D22 (Figure 3J). Taken together, our data indicated that most patients treated with AZA undergo drug incorporation and global DNA demethylation, and that the level of global demethylation in CD34⁺ HSPCs may be related to clinical response.

Pre-treatment DNA methylation at specific CpG sites correlates with clinical response

To further investigate the relationship between DNA methylation changes and clinical outcome we performed reduced representation bisulfite sequencing (RRBS) on longitudinal samples of BM CD34⁺ cells prior to, and immediately following, AZA treatment during cycle 1 and cycle 7 (Figure 4A). At baseline (C1D1), the number of CpGs detected with more than 10 reads (Figure S3A; range 2.4 - 3.6 million) and total reads in detected CpGs (Figure S3A; range 38.6 - 114.9 million) were similar between samples, and hierarchical clustering of all samples showed highest similarity within samples derived from the same patient (Figure S3B). Patients with MDS/CMML/AML generally have global hypermethylation ⁴⁵. However, at baseline $(C1D1)$, we observed relative hypomethylation in $CD34⁺$ cells of patients who responded to AZA compared to patients who did not respond (Figure 4B, Figure S3C), suggesting that differences in DNA methylation at diagnosis might influence patient outcomes. 23950 CpGs were hypomethylated in responders compared to non-responders and were predominantly located in CpG islands and promoter regions, while 3004 CpGs were hypermethylated in responders and were more frequently located in distal regions (Figure 4C). Since cytosine methylation is often concordant in proximity, we combined differentially methylated cytosines (DMCs) to regions (DMRs) prior to clustering baseline data. Patients clustered by response group, with the average methylation percentage of DMRs remaining consistent within response groups, indicating shared regions of differential methylation between individuals (Figure 4D). We then linked DMCs to target genes using HiChIP data generated from healthy HSPCs⁴⁶ and used pathway analysis to predict functional consequences of differential methylation between responders and non-responders. Genes associated with hypomethylated DMCs in responders included HOXA and HOXB cluster genes, GATA2, and SNAI1 (Figure 4E). The top 10 gene ontology analysis hits included pattern specification processes and regulation of epithelial cell migration (Figure S3Di); specific gene hits and their inclusion in selected pathways are shown (Figure 4E).

Baseline differences in CpG methylation suggests that CD34⁺ HSPCs might be epigenetically primed for AZA response in a subset of patients. To better understand how hypomethylated DMCs in responders might influence the global epigenetic environment, we overlapped baseline DMCs with global transcription factor (TF) and histone ChIPseq data from healthy HSPC subsets (HSC-multipotent progenitors (MPP), common myeloid progenitor (CMP), granulocyte-monocyte progenitor (GMP), megakaryocyte-erythroid progenitor (MEP)) 47. There was striking overlap between TF/histone binding and DMCs hypomethylated

in responders, but only at select histone marks for DMCs hypermethylated in responders (Figure 4F). Both hypo- and hyper-methylated DMCs showed overlap with H3K4me3 (promoter mark) and H3K27me3 (repressive mark) which together mark bivalent regions primed for epigenetic plasticity ^{48,49}. CTCF is involved in defining chromatin boundaries, and along with STAG2 belongs to the cohesin complex which facilitates looping of promoters to distal regulatory regions ^{50,51}. We observed enriched overlap with CTCF and STAG2 binding sites only at DMCs that were hypomethylated in responders (Figure 4F). Finally, overlap with TF binding sites was most prominent at FLI1-bound regions in CMPs and MEPs, and RUNX1 bound regions in CMPs. In CMPs and MEPs both FLI1 and RUNX1 bind regulatory regions of lineage specific genes that are subsequently expressed in mature myeloid or erythroid cells ⁴⁶ which are the specific cell populations that contribute to clinical response. Overall, we observe significant baseline CpG hypomethylation in patients who go on to respond to AZA, with the hypomethylated regions overlapping genes critical for blood development, and regulatory sites associated with epigenetic plasticity and lineage-specific gene regulation.

Longitudinal assessment of DNA methylation shows dynamic changes at specific CpG sites correlate with clinical response

We next looked at acute methylation changes immediately following the initial seven days of AZA treatment. Extensive hypomethylation was evident across all patients, with more than twice as many CpGs hypomethylated in responders compared to non-responders (Figure 5A; 23060 vs 9580). Hypermethylation compared to baseline was also observed at a very small number of CpGs (Figure 5A; 79 vs 40). While baseline methylation differences were mostly promoter-proximal, hypomethylation following AZA treatment was mostly at distal regions or within introns, regions which potentially correspond to enhancers (Figure 5A). We next compared overlap of specific DMCs between responders and non-responders (Figure 5B). Notably, 7572 CpGs were hypomethylated in both responders and non-responders; these comprised the majority of DMCs in non-responders. Gene ontology analysis of genes associated with the shared hypomethylated CpGs revealed a single enriched pathway (Figure S3Dii; immune response regulating signalling pathway). A further 15488 CpGs were uniquely hypomethylated in responders, while 2005 CpGs were uniquely hypomethylated in nonresponders. Importantly, genes associated with CpGs uniquely hypomethylated in responders were enriched for pathways relating to myeloid cell and osteoclast differentiation (Figure S3Diii, Figure 5C) suggesting clinical response to AZA is at least partly due to epigenetic reprogramming at gene loci required for HSPCs to differentiate and produce circulating progeny. Overlap of hypomethylated CpGs in responders at C1D8 with global transcription factor (TF) and histone ChIPseq data from healthy HSPC subsets revealed enrichment at regulatory regions, particularly at H3K27ac sites (active enhancer) in GMPs and MEPs, again consistent with improved differentiation capacity (Figure 5D).

Clinical response to AZA is generally not evident for several months following commencement of treatment $\frac{7}{1}$, and the substantial changes in CpG methylation that occur immediately following the initial treatment cycle may not persist over the long term. To evaluate sustained changes in CpG methylation we compared CpG methylation at C7D1 (after 6 AZA treatment cycles, but 3 weeks after the last AZA dose) to baseline methylation. Hypomethylation relative to baseline was observed in all patients, again skewed to distal regulatory regions, with approximately 3 times as many sites hypomethylated in responders compared to non-responders (Figure 5E; 889 vs 315). However, the overall number of hypomethylated sites was significantly reduced compared to C1D8, and there was no overlap in hypomethylated sites between response groups (Figure 5F). Gene ontology analysis of genes associated with hypomethylated CpGs in responders revealed enrichment in multiple pathways

including regulation of cell-cell adhesion and positive regulation of hemopoiesis; these pathways may reflect a marrow environment that is more supportive of blood production (Figure S3Div, Figure 5G).

Finally, to assess late AZA-responses in patients following long term AZA treatment we compared CpG methylation at C7D22 to C7D1 (Figure S3E). Surprisingly, we observed mostly hypermethylation in all patients, albeit at a very small number of genes (Figure S3E; responders - 106, non-responders - 83). Only 18 CpGs were hypomethylated in responders, and there was minimal overlap between treatment groups except for a single shared hypermethylated CpG (Figure S3F). Genes associated with the 18 CpGs hypomethylated in responders were enriched in pathways including regulation of signal transduction by p53 class mediator and regulation of mitotic cell cycle phase transition (Figure S3Dv, Figure S3G).

Overall, we observed that patients with clinical response to AZA have lower CpG methylation at baseline and undergo further CpG hypomethylation at regions associated with genes involved in myeloid cell differentiation. Furthermore, changes in CpG methylation that persist following 6 cycles of AZA treatment are also enriched for genes involved in haematopoiesis and leukocyte differentiation.

Variant alleles persist over the course of AZA treatment irrespective of clinical response

Improved peripheral blood counts, which are the hallmark of clinical response to MDS/CMML, arise via improved blood production originating from CD34⁺ HSPCs. An ongoing question has been whether AZA treatment clears mutated HSPC clones from the bone marrow facilitating expansion of residual healthy stem cells, or conversely, reprogrammes mutated cells such that blood output is increased. We have previously shown in a smaller MDS/CMML cohort that increased output from mutated progenitors accompanies clinical response ³⁶. Here, we tracked

mutations in a panel of 111 genes associated with myeloid pathologies (Table S6) across the course of AZA treatment (Table S7). Our cohort had baseline mutational profiles typical of MDS/CMML/AML ⁵² with the most frequent mutations occurring in *TET2* (10/28; 35.7%), *RUNX1* (10/28; 35.7%), *SRSF2* (9/28, 32.1%), and *TP53* (8/28; 28.6%) (Figure S4A, Figure S4B).

Most patients had stable sub-clonal composition across treatment phases irrespective of clinical outcome (Figure 6A). Three patients showed substantially reduced mutational burden corresponding to clinical response at C6D28 with subsequent reappearance of the mutated clone at progression (Figure 6A; blue arrows indicate P20, P18, P06). Conversely, two patients were initially non-responders but showed a delayed response; in both cases mutational burden was initially stable but reduced at the time of response (Figure 6; orange arrows indicate P07, P09). We observed patients with sustained response but fluctuating mutational burden (Figure 6B; P01), patients with stable mutational burden across initial response and subsequent progression (Figure 6B; P05), and patients with decreasing mutational burden in the absence of clinical response (Figure 6B; P08). Overall, mutational burden did not correspond to clinical response, or to global demethylation kinetics (Figure 6B, *lower panels*).

Finally, we asked whether there was any relationship between shift in specific mutated alleles and global demethylation across the corresponding treatment phase, focussing on the most highly mutated genes. We did not observe any correlation between demethylation and shifts in mutated allele frequency (Figure 6C); furthermore, with the exception of *TET2* (and possibly *TP53),* change in mutation frequency did not differ based on response status (Figure S4C). Thus, although sub-clonal structures of gene mutations showed temporal variation, most variant alleles persisted through both phases of treatment irrespective of clinical response or demethylation kinetics.

Discussion

In this study we measured longitudinal *in vivo* drug incorporation and DNA methylation dynamics in a cohort of patients treated with injected and oral formulations of AZA. Crossover to oral AZA (100-150mg bd, 21/28days) was generally well tolerated, despite some gastrointestinal toxicities, in a patient cohort with outcomes comparable to historical data^{7,8}. Global DNA methylation levels in mononuclear cells were comparable in AZA responders and non-responders during their course of treatment. However, in responders we observed distinct baseline and early drug-induced differences in CpG methylation in CD34⁺ HSPCs that overlapped regulatory regions of genes associated with tissue patterning, cell migration and myeloid differentiation. After six treatment cycles, and concomitant with clinical response, differential hypomethylation in HSPCs mapped to genes involved in positive regulation of hemopoiesis and cell-cell adhesion, suggesting adaptations in the bone marrow as a driver of enhanced haematopoiesis in responders. Overall, these data suggest that specific CpG methylation differences in HSPCs may contribute to variable response to AZA.

Global DNA demethylation in PB and BM MNCs was not proportionate to *in vivo* DAC incorporation, and was not a reliable measure of clinical response. By contrast, HSPCs in responders had lower baseline CpG methylation than in non-responders, and these relatively hypomethylated CpGs mapped to pathways involved in tissue patterning and cell migration. Whilst a larger study is required to ascertain whether baseline CpG methylation at specific sites in HSPCs is predictive of clinical response, these data suggest that HSPCs in some individuals may be epigenetically primed to respond to AZA, and point to pathways that may be associated with such a response. Indeed, hypomethylated DMCs in responders mapped to regions with bivalent histone marks or bound by key hematopoietic TFs in healthy HSPCs ⁴⁶. Genomic regions with these features are associated with driving myeloid and megakaryocyte-erythroid differentiation. The origin of baseline CpG methylation differences in HSPCs, and whether they are related to specific genetic features or the phylogenetic age of the mutated clone is unclear. However, these data provide a foundation for more granular investigations of DNA methylation and variant alleles at single cell resolution ⁵³.

In healthy HSPCs, key TFs are pre-emptively bound at regulatory regions of lineage specific genes 46. CpG hypomethylation in MDS HSPCs during the first AZA cycle was skewed to non-coding regions, and in responders, mapped to pathways involved in activating myeloid programs. This feature that may have facilitated early myeloid differentiation of these cells. Following multiple cycles of AZA when response was clinically apparent and HSPC populations have likely changed from those at baseline, only a small set of CpGs were hypomethylated, with top enriched pathways including cell-cell adhesion and positive regulation of hemopoiesis and leukocyte differentiation that pointed to altered relationships with other cells in the bone marrow microenvironment.

MDS/CMML are driven by somatic mutations in HSCs, and there is increasing evidence that highly mutated stem cells with altered differentiation capacity contribute to improved peripheral counts in responders ³⁶. Indeed, most patients in this cohort had stable clonal composition over treatment phases, regardless of response status, drug incorporation or global demethylation. What remains unclear is whether specific CpG demethylation and improved differentiation capacity occur in most cells, or whether reprogramming of a small fraction of mutant stem cells is sufficient to improve circulating output. This has implications for disease progression as mutated stem cells that do not regain differentiation capacity may persist as a cellular reservoir for progressive disease.

Overall, this study revealed that clinical response was not related to how much global demethylation occurred during treatment, but rather to demethylation of specific CpG sites in HSPCs. Due to limitations with sample material, we only evaluated differences in pooled CD34+ fractions using RRBS; genome-wide evaluation of CpG methylation in HSPC subfractions may reveal further insights into differentially methylated CpGs that regulate HMA response. Furthermore, this study focussed on cell-intrinsic effects in HSPCs and their progeny. HMAs potentially affect any replicating cell in the BM, and the interplay between the BM microenvironment and mutated HSPCs are involved in pathogenesis of MDS ⁵⁴⁻⁵⁷; thus AZAinduced effects on additional cell types in the bone marrow may modulate clinical response to HMAs. Nevertheless, this study uncovered specific regions in HSPCs where demethylation was associated with therapeutic effects, and such regions are of value not only as a gauge for early HMA response assessment but also as potential sensors for screening novel agents or as targets for site-directed demethylation therapies.

Online Methods

Trial design, patients, and oversight

Participants were recruited to an open label phase 2 multicentre investigator-initiated trial (NCT03493646: Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC-486). Participants who commenced treatment received 6 cycles of parenteral AZA (75 mg/m²/day administered subcutaneously for 7 days followed by a rest period of 21 days) followed by 6 cycles of oral AZA (2 cycles at 100mg bid, 4 cycles at 150mg bid for 21 days, followed by a rest period of 7 days) (Figure 1A), and were followed up for a further 12 months. Patients were eligible for enrolment following a new diagnosis of HR-MDS (IPSS; intermediate-2 or high-risk), CMML (bone marrow [BM] blasts 10-29%), or LB-AML (20- 30% blasts). 53 patients were assessed for eligibility and 40 commenced treatment (Figure 1B). Pharmacodynamic sampling was performed throughout the treatment period (Figure 1A), and clinical response assessed at the end of cycle 6 (C6D28) and end of cycle 12 (C12D28).

When indicated, best supportive care was allowed in combination with study treatment and included red blood cell or platelet transfusion, antibiotics, antifungals, antivirals, antiemetics, anti-diarrhoeal agents, and granulocyte colony-stimulating factor (G-CSF). Use of erythropoiesis stimulating agents and hematopoietic growth factors other than G-CSF was excluded. Patients were monitored prior to commencement of each treatment cycle with a physical exam, vital signs, haematology, biochemistry, liver function, and ECOG assessment. Criteria for discontinuation included lack of efficacy, progressive disease, withdrawal by participant, adverse event(s), death, lost follow-up, protocol violation, study termination by the sponsor, pregnancy, recovery, non-compliance with azacitidine, transition to commercially available treatment, physician decision, disease relapse, and symptomatic deterioration. Actual reasons for discontinuation were as shown (Figure 1B).

The trial was funded by Celgene and sponsored by the University of New South Wales. The Kirby Institute, UNSW was responsible for trial coordination. The protocol received ethical approval from the South Eastern Sydney Local Health District Human Research Ethics Committee, and participating sites received Institution approval to conduct the trial prior to commencing recruitment. All participants provided written informed consent. A protocol steering committee oversaw the trial, and independent adjudicators confirmed clinical response assessments provided by attending clinicians. Serious adverse events were recorded during the oral AZA cycles only and were assessed by independent medical monitors. J.O. led the statistical analyses with assistance from J.A.I.T., F.Y., and F.C.K. All authors had access to trial data.

Primary and secondary trial outcomes

The primary objective was to determine whether there is greater AZA incorporation in DNA following 21 days of oral AZA compared to 7 days of injection AZA in a 28- day treatment cycle, and whether incorporation was associated with greater clinical and/or molecular response.

Secondary objectives of the trial were based on a previous study where patients who responded to injection AZA had a greater fraction of cycling HPCs compared to patients who fail to respond ¹⁶. However, whether increased replication is associated with increased AZA incorporation was not known. The availability of an assay 41 to measure AZA incorporation, and the ability to measure the fraction of replicative HPCs, forms the basis of the secondary objectives of this study.

Statistical analyses

Statistical comparisons for cell cycle, AZA-MS in BM, LINE-1 qPCR, and VAF data were performed in python $(v3.8.3)$ using the scipy $(v1.10.1)$ stats module. Single timepoint comparisons between outcome groups used the function stats.ttest ind() while comparisons between timepoints used the function stats.ttest rel(). Correlations were tested using the function stats.spearmanr(). In all cases, P values <0.05 were considered significant.

Drug incorporation into DNA and global DNA methylation levels were compared for responders and non-responders, or for injected and oral phases, using a linear mixed model approach with subject-level random effects to account for within-subject variability. Drug incorporation into PB cells and global DNA methylation levels were compared over collection timepoints (D1, D8, D22) for responders and non-responders, or for injection and oral phases, using a linear mixed model approach with subject-level random effects to account for withinsubject variability. Linear mixed model approaches utilised SAS software.

Processing of BM and PB

Peripheral blood (20mL per timepoint in addition to standard of care collection) was collected in 10mL EDTA vacutainers. Immediately following collection, 1mL of 1mg/mL tetrahydrouridine (THU; abcam #ab142080) was added per tube, and the specimen rocked at 4°C until processing. Blood was centrifuged at 800g for 10min at room temperature, upper plasma layer removed and stored at -80°C, and the remaining red cell/buffy coat fraction treated with two rounds of 1X red blood cell lysis buffer (BD Pharm Lyse #555899). Mononuclear cells (MNCs) were recovered by centrifugation at 800g and pellets snap frozen at -80°C for subsequent DNA and RNA isolation.

Bone marrow aspirates (BMA; 30mL per timepoint in addition to standard of care collection) were collected into 10mL Hanks balanced salt solution (Life Technologies #14170- 161) containing 100IU/mL porcine heparin (Pfizer). Immediately following collection, 4mL of lmg/mL THU was added, and the specimen rocked at 4°C until processing. BMA samples were diluted 1:4 with RPMI medium (Gibco #21870092), underlaid with 10mL Lymphoprep (Axis-Shield #1114547), and centrifuged at 800g for 35min at RT. The upper plasma layer was removed and snap frozen at -80°C, and MNCs collected for storage (pellets for DNA/RNA isolation or viably frozen) or further processing. $CD34^+$ cells were isolated using $CD34^+$ microbeads (Miltenyi #130-046-703) and an AutoMACS machine (Miltenyi). Cell purities were monitored using flow cytometry (APC-CD34 Miltenyi # 130-113-176) and CD34⁺ and CD34 depleted cells were viably frozen for later use.

Isolation of DNA and RNA

DNA and RNA were isolated from frozen cell pellets or thawed CD34⁺ cells using either an All-in-One DNA/RNA miniprep kit (BioBasic #BS88203) or an AllPrep DNA/RNA mini kit (Qiagen #80204) and quantified using either a Nanodrop spectrophotometer (Thermo) or a Qubit fluorometer (Thermo) using a Quant iT Qubit dsDNA HS Assay Kit (Invitrogen #Q32851).

Cell cycle analysis

Up to two million thawed bone marrow mononuclear cells (MNCs) were washed and resuspended in flow cytometry buffer (2% fetal bovine serum, 1mM EDTA in PBS) containing human Fc block (BD Biosciences). Cells were first stained with a PE-Cy5 lineage marker cocktail (CD2 (clone RPA-2.10), CD3 (clone HIT3a), CD10 (clone HI10a), CD19 (clone HIB19), CD20 (cone 2H7) and GPA/CD235ab (clone HIR2); BioLegend) for 15 minutes on ice, then washed and fixed with 1.6% paraformaldehyde for 10 minutes at room temperature and permeabilised using 90% ice-cold methanol for 30 minutes on ice. Fixed, permeabilised cells were then incubated with CD34-PE (clone 8G12, BD Biosciences), CD38-APC/Fire 750 (clone HIT2, BioLegend), and Ki67-AF488 (clone B56, BD Biosciences) antibodies for 1 hour at room temperature in the dark. Cells were washed twice then stained in 0.5µg/mL of 4',6 diamidine-2-phenylidole dihydrochloride (DAPI, BD Biosciences) for 15 minutes at room temperature and data acquired on a LSRFortessa (BD) flow cytometer at the Mark Wainwright Analytical Centre (UNSW Sydney). Data was analysed using FlowJo software (Tree Star, USA). HSC samples containing less than 50 cells were excluded from analysis.

Measurement of DAC incorporation and DNA methylation using mass spectrometry (AZA-MS)

DNA DAC incorporation and demethylation was measured by mass spectrometry (AZA-MS) ⁴¹ at all collection time points. Briefly, 250pmol 5-Aza-2'-deoxy Cytidine-15N4 (15N-DAC; Toronto Research Chemicals $# A79695$) was spiked-in to $5\n-10\mu$ g purified DNA in a total volume of 30µL. After addition of 10µL of 20mg/mL NaBH4, samples were incubated for 20 min at room temperature with agitation. The pH was then neutralised by addition of 1µL 2M HCl. DNA was then fragmented by addition of 30μ L of fragmentation mixture (100U/mL benzonase (Sigma-Aldrich #E1014), 240U/mL phosphodiesterase I (Sigma-Aldrich #P3243), 40U/mL alkaline phosphatase (Sigma-Aldrich #P7923), 20mM Tris-HCl pH 8.0, 20mM NaCl, 3mM MgCl₂) and incubation for one hour at 37°C. Fragmented samples were dried under vacuum (Savant Speedvac Plus SC210A, Thermo) and stored at -80°C prior to mass spectrometry analysis. Standard curves for all measured analytes (Decitabine (DAC; Selleck Chemicals #S1200), Cytidine (C; Selleck Chemicals #S2053), 5-methylcytidine (mC; Cayman Chemical #16111), 2'deoxycytidine (dC; Cayman Chemical #34708), 2'deoxy-5 methylcytidine (mdC; MMP Biomedicals # 0219888310-10mg)) were prepared in parallel and covered the following ranges; DAC, 0.3-40pmol, C/dC, 3-100pmol, mC/mdC, 0.06 – 2pmol, all per 20µL injection.

Samples were reconstituted in 50µL CE buffer (10mM Tris HCl pH 9.0, 0.5mM EDTA) and run on a Q Exactive PLUS Orbitrap mass spectrometry system (Thermo) using a heated electrospray interface operated in the positive ion mode. Chromatographic separation was performed on a 100 mm \times 2.1 mm i.d., 3 μ M, C30 column (Acclaim, Thermo) at 40 °C. Duplicate 20µL injections of each sample were analysed using gradient elution with 0.1% formic acid in Milli-Q water (Solvent A) and 0.1% formic acid in acetonitrile (Solvent B) at a flow of 0.4 ml/min over 8 min. Mass spectra were acquired at a resolution of 140 000 over the range of 220 to 260 Th with the electrospray voltage at 4000 V. Sheath gas pressure and auxillary gas pressure were 27 and 10. The capillary temperature was 300 °C and the s-lens was 80 V. Data processing of chromatograms was performed using the Quanbrowser function of the Xcalibur Software package version 2.5 (Thermo) and analyte measurements used to calculate pmol DAC detected per µg of input DNA and DNA methylation relative to C1D1 levels ($\text{[mdC/dC timepoint]} \div \text{[mdC/dC C1D1]}.$

qPCR-based measurement of DNA demethylation at LINE-1 elements

LINE-1 qPCR was performed essentially as described ⁴⁴ and using the same primers except for

TGGCTGTGGGTGGTGGGCCTCGTAGAGGCCCTTTTTTGGTCGGTACCTCAGATGG

AAATGTCTT/3ddC/. Technical replicates of up to 4 ng of DNA in PCR master mix (20mM Tris-HCl pH 8.4, 50mM KCl, 7mM MgCl₂, 0.2mM dNTP mix (dATP, dCTP, dGTP, dTTP), DraI-cut specific oligonucleotides (12.5nM each of forward and reverse F-oligos plus 160nM each of forward and reverse outer primers and HEX probe), HpaII-cut specific oligonucleotides (2nM each of forward and reverse F-oligos plus 40nM each of forward and reverse outer primers and FAM probe), 2U HpaII (NEB #R0171L), 1U DraI (NEB #R0129L), 0.5U Hot Start Taq DNA Polymerase (NEB #M0495L)) were cycled at 37°C for 15 min; 90°C for 5 s; 95°C for 2 min; then 10 cycles of 90°C for 5 s, 95°C for 15 s, 60°C for 1 min, and 68°C for 20 s; followed by 40 cycles of 95°C for 15 s, 65°C for 40 s, and 68°C for 20 s in a CFX96 realtime PCR machine (BioRad). Efficiency of the FAM and HEX reactions was calculated using a standard curve over the range 6.25 pg - 4 ng per reaction, generated from AZA-treated cellline DNA. The LINE-1 demethylation level for each cycle of each patient was normalized to the corresponding C1D1 sample using the following formula:

Relative LINE1 demethylation =
$$
\frac{Efficency (FAM)^{ct(FAM, C1D1)-ct(FAM)}}{Efficency (HEX)^{ct(HEX, C1D1)-ct(HEX)}}
$$

Reduced representation bisulphite sequencing (RRBS)

RRBS libraries were constructed from 50ng genomic DNA using an Ovation RRBS Methyl-Seq system (Tecan). Bisulphite conversion was performed using the Epitect Fast DNA Bisulfite kit (Qiagen) and libraries amplified using the Ovation RRBS Methyl-Seq system (Tecan). Libraries were sequenced on a Novaseq 6000 using the SP100 flow cell (Illumina) at Monash University's School of Translational Medicine Genomics Facility.

Raw RRBS data in fastq format were quality and adapter trimmed according to the manufacturer's guide using trim galore $(0.6.4)$ and a custom trimming script 58 . The trimmed fastq files were then aligned to a bisulfite converted genome (hg38) using Bismark (0.22.3) and methylation status at each CpG locus were extracted ⁵⁹. Differentially methylated cytosines (DMCs) were identified using methylKit (1.22.0) incorporating patient ID as a covariate when available and differentially methylated regions (DMRs) were identified with edmr (0.6.4.1) packages in R $(4.2.0)$ ^{60,61}.

DMCs and DMRs were annotated using ChIPseeker (1.32.1) for the nearest gene and annotatr (1.22.0) for CpG island annotation $62,63$. DMCs were further annotated using HiChIP data from healthy HSPC subsets 46. DMCs were first linked to significant HiChIP interaction at 5kb resolution, and then associated with genes if the DMC-containing bin was within 10 kb of the TSS of specific genes. Gene ontology enrichment was performed using HiChIP associated genes, and visualized using clusterProfiler $(4.11.0.001)^{64}$. ChIP-seq peaks ⁴⁶, including TF and histone modifications from different cell types, were used to evaluate the enrichment of DMCs in key regulatory regions. DMCs were first expanded 100bp on both sides and overlapped regions were merged. The regioneR package (1.28.0) was used to generate 100 sets of randomized regions with matched characteristics, and the z-score was calculated as (observe - mean)/sd and visualized 65.

Myeloid capture panel sequencing and analysis

DNA from BM MNCs at baseline and clinical response timepoints was utilised for assessment of VAFs using a myeloid gene capture panel with sensitivity to detect VAFs at or above 5%. Capture sequencing library construction and sequencing was performed at the University of

Auckland using standard clinical myeloid capture arrays (Table S7). Sequencing data quality was assessed with fastqc tool (v0.11.5) followed by BWA alignment to the hg19 reference genome (v0.7.12). Sam files were converted to bam format and sorted using samtools (v1.3.1) and mpileup files generated using the following parameters: maximum depth (-d) of 1000, minimum base quality (-Q) of 15 and minimum mapping quality (-q) of 10. Variants were called using Varscan (v 2.3.9) to generate VCF (variant call format) files using the following parameters: minimum coverage (--min) of 8, minimum depth of the reads supporting the variant (--min-reads2) of 2, minimum variant frequency (--min-var-freq) of 0.01 and strand filter (--strand-filter) 0. Variants were annotated using ANNOVAR 66 and SnpEffect 67 .

Variants were filtered to remove those occurring at a minor allele frequency of greater than 0.1% in gnomAD 68 , ExAC 69 , and 1000 genomes 70 databases. Then any variant belonging to a blacklist of known false positives and any variant at a VAF of less than 5% were excluded.

Acknowledgements

Patients and their carers, clinicians, and trial coordinators at recruiting sites, Celgene/BMS (Dr Jessica Morison, Dr Tamara Etto, Ms Dharini Fernando, Dr Kyle MacBeth, Dr Kevin Lynch, Dr Han Mynt, Dr Du Lam, Ms Tracey Crivellaro, and Dr Amir Samuel), UNSW (Mr Alan Melrose and Dr Qiao Qiao), SESLHD (Ms. Deborah Adrian and Ms Karen Mccardie), and Scientia Clinical Research (Ms Lisa Nelson) for input during protocol development, trial set up and follow-up. Some of the data presented in this work was acquired by personnel and/or instruments at the Mark Wainwright Analytical Centre (MWAC) of UNSW Sydney, which is in part funded by the Research Infrastructure Programme of UNSW. The investigator initiated clinical trial was funded in part by Celgene/BMS (RG172029) with research support from the National Health and Medical Research Council (RG170246, RG211412), Anthony Rothe Memorial Trust (RG182042, RG202657, RG213236), Leukaemia Foundation (RG231257). Patients were eligible for and received injection azacitidine from the pharmaceuticals benefit scheme (Australia) and CC-486 from Celgene/BMS.

Authorship contributions

J.E.P designed the research study and served as the lead PI on the clinical trial. C.L., wrote the trial protocol and M.N.P. oversaw the clinical trial. J.A.I.T., F.Y. H.R.H, S.J., J.S, C.H.S., X.Y.L., A.C.N., P.M.K, G.S.B., X.Z., M.N., E.S.G., and F.C.K. performed research and analysed data. J.A.I.T., F.V., R.P., M.J.R., C.J.J., S.K.B., D.J.C., J.W.H.W., A.U., M.N.P., and J.E.P. provided research supervision. S.D. and S.H. coordinated the clinical trial. G.B., M.B., Y.G., N.A. provided help with trial coordination and database design. L.V., L.P., C.Y.F., M.K., D.K.H., R.I.S., S.M., L.L., F.H.P., S.R.L., K.J.S., K.K.S., P.R., P.P., W.S.S., S.L., C.T., S.J.F., F.R., A.K.E., D.H. and M.H. assisted with the trial. J.O. performed and oversaw statistical analysis. J.A.I.T and J.E.P. wrote the manuscript. All authors have viewed and approved the manuscript.

Disclosures of conflicts of interest

F.V. is affiliated with OmniOmics.AI Pty Ltd. C.F. is an advisory board member at Amgen, AbbVie, Adaptive Biotech, BeiGene, Pfizer, Otsuka, and Jazz, a consultant at Novotech, and received speaker fees from Amgen, Pfizer, Servier, BMS, and Astella. D.H. has consultancy agreements with GlaxoSmithKline and Pharming Corp. M.H. is a consultant/advisory board member at Roche, Gilead, Otsuka, Janssen, Beigene, and Takeda. M.N.P. received research funding and/or provision of drug for clinical trials (to institution) from AstraZeneca, BRII Biosciences, Celgene/BMS, CSL Behring, Eli Lilly, Emergent Biosciences, Gilead Pharmaceuticals, GlaxoSmithKline, Grifols, Janssen/Johnson and Johnson, Takeda, ViiV Pharmaceuticals and has advisory roles with Celgene/BMS, Gilead Pharmaceuticals, and ViiV Pharmaceuticals. J.E.P. received research funding and/or provision of drug for clinical trials (to institution) from Celgene/BMS, Astex, Verastem Oncology and received honoraria from Abbvie as an advisory board member. The remaining authors declare no competing financial interests.

Figure legends

Figure 1: Trial design and patient outcomes. (A) Trial design showing dosing schedule, specimen collection, and IWG assessment timepoints for injected and oral phases. **(B)** Consort diagram summarising outcomes for all participants who were assessed for eligibility. **(C)** Swimmer plots showing participant response and outcome over time. Colored squares indicate diagnosis for each patient (yellow – high risk (HR) MDS, purple – CMML, brown – low blast (LB) AML). Circles show response at IWG assessment or progression timepoints (blue – responder, orange – non-responder). The off-study reason for each patient is as indicated, the number in brackets indicates the number of treatment cycles completed, * denotes a single patient (P21) who was accelerated to the oral phase following 4 injection cycles.

Figure 2: Cell cycle status at diagnosis and across treatment cycles

(A) Schematic showing analysis workflow for determining cell cycle parameters in CD34⁺ $CD38^{lo}$ stem (HSC) and $CD34⁺ CD38^{hi}$ progenitor (HPC) cells. Schematic partially created with BioRender.com **(B)** Percentage of HSCs in **(i)** $S/G_2/M$, **(ii)** G_0 , **(iii)** G_1 cell cycle phases. **(i-iii)** *Left:* percentage of cells in specified cell cycle phase at diagnosis (C1D1), coloured by clinical outcome at the end of the injection phase. *Right:* Percentage of cells in specified cell cycle phase at diagnosis (C1D1) and at the end (C6D28) of the injection phase. Lines indicate paired samples from a single patient, only patients with data at C1 and C7 are shown. *** *P* < 0.001, ** *P* < 0.01, * *P* < 0.05 unpaired (*left*) or paired (*right*) t-test. **(C)** Percentage of HPCs in **(i)** $S/G_2/M$, **(ii)** G_0 , **(iii)** G_1 cell cycle phases. **(i-iii)** *Left:* percentage of cells in specified cell cycle phase at diagnosis (C1D1), coloured by clinical outcome at the end of the injection phase. *Right:* Percentage of cells in specified cell cycle phase at diagnosis (C1D1) and at the end (C6D28) of the injection phase. Lines indicate paired samples from a single patient, only patients with data at C1 and C7 are shown. *** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$ unpaired (*left*) or paired (*right*) t-test. **(D)** Percentage of HPCs in S/G2/M following 12 treatment cycles, coloured by clinical outcome at C12D28. *** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$ unpaired ttest. **(E-F)** Relationship between cell cycle status and drug incorporation and DNA demethylation during cycle 1 in **(E)** HSCs and **(F)** HPCs. **(E-F)** Percentage of cells actively cycling (S/G2/M phase) at C1D1 compared to maximum drug incorporation (*left*) and minimum DNA methylation (*right*) in peripheral blood (PB) during the same cycle. Dashed lines indicate baseline values. Gray dots indicate patients for whom response data is unavailable. $r =$ spearman correlation coefficient.

Figure 3: DAC incorporation and relative DNA methylation across treatment phases. (A) Schematic showing administration of azacitidine (5-AZA-C), *in vivo* modification, and incorporation into DNA leading to trapped and degraded DNMT1 and DNA hypomethylation. Drug incorporation into DNA is directly assessed by measuring NaBH4-stabilised and fragmented DNA (dihydro 5-AZA-dC ribonucleotide (R)) by mass spectrometry. Changes in DNA methylation were assessed either by mass spectrometry-based comparison of mdC to dC ratio pre- and post-treatment or by measuring demethylation of LINE-1 promoter elements as a proxy for global demethylation. Schematic partially created with BioRender.com **(B-C)** Drug incorporation and DNA methylation (relative to baseline) during the injection phase in patients who either progressed or completed the treatment phase and underwent IWG disease assessment to determine response status ($n = 26$ [Responder (R): 16, Non-responder (NR): 10]). **(B)** Drug incorporation in responders and non-responders at all sample points (*left*) or separated by cycle day (*right*). All statistical comparisons for panels B-G were performed using a linear mixed model approach, *P* values are as indicated (*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$, ns *P* > 0.05). **(C)** Relative DNA methylation at all sample points *(left)* or separated by cycle day

(*right*). **(D-E)** Drug incorporation and DNA methylation during the injection and oral phases of the study ($n = 29$ patients during injection phase, $n = 19$ patients during oral phase); data analysis for the oral phase was restricted to cycles 9 and later to minimise the likelihood of detecting changes carried over from the injection phases. **(D)** DAC incorporation during the injection and oral phase at all sample points (*left*) or separated by cycle day (*right*). **(E)** Relative DNA methylation at all sample points (*left*) or separated by cycle day (*right*). **(F-G)** Drug incorporation and DNA methylation during the oral phase of the study: data analysis was restricted to cycles 9 and later to minimise the likelihood of detecting changes carried over from the injection phases (n = 19 patients, R = 8, NR = 11). Response status is based on IWG assessment at end of cycle 12 when available $(n = 11)$; patients who progressed during the oral phase or soon after stopping treatment were assessed as non-responders ($n = 6$), and remaining patients were assigned response as per end of cycle 6 IWG assessment (n = 2). **(F)** DAC incorporation in responders and non-responders at all sample points (*left*) or separated by cycle day (*right*). **(G)** Relative DNA methylation at all sample points (*left*) or separated by cycle day (*right*). **(H)** Relative DNA methylation in bone marrow mononuclear cells at C1D8, C7D1, and C7D22 compared to pre-treatment. *Left:* aggregate data at each timepoint. *Right:* Plot showing longitudinal methylation changes in individual patients. Statistical comparisons for panels H and J were performed using the ttest ind function from scipy.stats, *P* values are as indicated * $P < 0.05$, ns $P \ge 0.05$) (I) Comparison of methylation changes measured by mass spectrometry or LINE-1 PCR assay in bone marrow mononuclear cells. Individual samples are plotted along with the linear regression line with 95% confidence interval. **(J)** Relative DNA demethylation in bone marrow CD34⁺ cells at C1D8, C7D1, and C7D22 compared to pre-treatment. *Left:* aggregate data at each timepoint. *Right:* Plot showing longitudinal methylation changes in individual patients.

Figure 4: Baseline differences in site-specific methylation correlate with clinical response to AZA

(A) Schematic showing sample collection timepoints for reduced representation bisulphite sequencing (RRBS). **(B)** Average methylation at CpG sites at baseline (C1D1). Statistical comparison is unpaired t-test, $*$ indicates $P < 0.05$. (C-F) Comparison of responder (n = 10) and non-responder $(n = 8)$ patients prior to commencing AZA therapy. **(C)** Upper bar shows genomic distribution of 440140 CpG sites with data in all samples at C1D1 and C1D8. Lower bars show genomic distribution of CpGs which were hypomethylated ($n = 23950$) or hypermethylated (n = 3004) in responders compared to non-responders. **(D)** Clustered heatmap showing differentially methylated regions across all patients, with clinical response as indicated. **(E)** Network diagram showing enriched pathways for genes mapping to CpGs which are hypomethylated in responders at baseline. Network diagrams were created using clusterProfiler. CpGs were annotated to genes using HiChIP data from healthy human HSPC subsets 46. **(F)** Enrichment of differentially methylated CpGs at genomic regions with specific histone marks (H3K27Ac, H3K3me3, H3K27me3) or bound by key transcription factors and genome organisers (FLI1, ERG, PU.1, GATA2, RUNX1, TAL1, LYL1, LMO2, Pol2, CTCF, STAG2) in healthy human HSPC subsets. Plot shows CpG regions hypermethylated (*upper*) or hypomethylated (*lower*) in responders compared to non-responders.

Figure 5: Acute and sustained changes in site-specific methylation following AZA treatment

(A-D) Acute methylation changes at 440140 CpG sites detected in all samples at C1D1 and C1D8 following the first cycle of AZA treatment. **(A)** Genomic distribution of CpG sites differentially methylated at C1D8 compared to baseline C1D1 in responders and nonresponders. **(B)** Upset plot showing overlap of differentially methylated CpG sites between comparison groups. **(C)** Network diagram showing enriched pathways for genes mapping to CpGs which are uniquely hypomethylated in responders at C1D8 compared to C1D1 ($n =$ 15488 CpGs). Network diagrams were created using clusterProfiler. CpGs were annotated to genes using HiChIP data from healthy human HSPC subsets 46. **(D)** Enrichment of differentially methylated CpGs at genomic regions with specific histone marks (H3K27Ac, H3K3me3, H3K27me3) or bound by key transcription factors and genome organisers (FLI1, ERG, PU.1, GATA2, RUNX1, TAL1, LYL1, LMO2, Pol2, CTCF, STAG2) in healthy human HSPC subsets. Plot shows CpG regions hypermethylated (*upper*) or hypomethylated (*lower*) at C1D8 compared to C1D1 in responders. **(E-G)** Sustained changes in site-specific methylation. **(E)** Genomic distribution of CpG sites differentially methylated at C7D1 compared to baseline in responders and non-responders. **(F)** Upset plot showing overlap of differentially methylated CpG sites between comparison groups. **(G)** Network diagram showing enriched pathways for genes mapping to CpGs which are hypomethylated in responders at C7D1 compared to C1D1 ($n = 889$ CpGs). Network diagrams were created using clusterProfiler. CpGs were annotated to genes using HiChIP data from healthy human HSPC subsets 46 .

Figure 6: Variations in clonal composition during HMA treatment

(A) Variant allele shifts in each patient over (*left*) injection phase, and (*right*) oral phase. Each column shows an individual patient with heatmap representation of VAF for each variant allele at start and end of the treatment phase (or where relevant during the oral phase, at progression). Bar plots are coloured by clinical response across the relevant treatment phase. **(B)** Clonal shifts in representative patients. *Upper panels:* Nightingale plots show VAF for each variant at

diagnosis (C1), following 6 treatment cycles (C7) and following 12 treatment cycles/at progression (C12). *Lower panels:* Methylation level relative to C1D1 in PB across the entire course of treatment. **(C)** Correlation between global changes in methylation and shifts in variant allele burden for the four most frequently mutated genes in this cohort. Plots show composite data; each data point indicates a change in VAF across either injection or oral treatment phase and the average global methylation relative to C1D1 over the same treatment phase. $r =$ spearman correlation coefficient.

References

1. Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. *Nat Med*. 2019;25(1):103-110.

2. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ, Chronic Myeloid Disorders Working Group of the International Cancer Genome C. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616-3627; quiz 3699.

3. Carr RM, Patnaik MM. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia. *Curr Opin Hematol*. 2020;27(1):2-10.

4. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Gohring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellstrom-Lindberg E, Linnarsson S, Jacobsen SE. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. *Cancer Cell*. 2014;25(6):794-808.

5. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med*. 2011;364(26):2496-2506.

6. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, Yoshida K, Roller A, Nadarajah N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Kohlmann A, Miyano S, Haferlach C, Kern W, Ogawa S. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia*. 2014;28(2):241-247.

7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDSSSG. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009;10(3):223-232.

8. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J Clin Oncol*. 2002;20(10):2429-2440.

9. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood*. 2014;124(17):2705-2712.

10. Platzbecker U. Treatment of MDS. *Blood*. 2019;133(10):1096-1107.

11. Jen EY, Wang X, Li M, Li H, Lee SL, Ni N, Przepiorka D, Vallejo J, Leong R, Ma L, Gehrke BJ, McLamore S, Theoret MR, de Claro RA. FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy. *Clin Cancer Res*. 2022;28(14):2989-2993.

12. Lee T, Karon M, Momparler RL. Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. *Cancer Res*. 1974;34(10):2482-2488.

13. Momparler RL, Derse D. Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. *Biochem Pharmacol*. 1979;28(8):1443-1444.

14. Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. *Cancer Res*. 1970;30(11):2760-2769.

15. Li LH, Olin EJ, Fraser TJ, Bhuyan BK. Phase specificity of 5-azacytidine against mammalian cells in tissue culture. *Cancer Res*. 1970;30(11):2770-2775.

16. Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. *Cell Rep*. 2017;20(3):572-585.

17. Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. *Int J Cancer*. 2008;123(1):8-13.

18. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. *Mol Cell Biol*. 2005;25(11):4727-4741.

19. Stomper J, Rotondo JC, Greve G, Lubbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMAbased therapies. *Leukemia*. 2021;35(7):1873-1889.

20. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, Fernandez H, Tallman MS, Greally JM, Carraway H, Licht JD, Gore SD, Melnick A. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. *Blood*. 2009;114(16):3448-3458.

21. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. *Blood*. 2009;114(13):2764-2773.

22. Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, Lichti CF, Meyer MR, Townsend RR, Wilson RK, Mardis ER, Ley TJ. Genomic impact of transient low-dose decitabine treatment on primary AML cells. *Blood*. 2013;121(9):1633-1643.

23. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Budhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Merghoub T, Chan TA, Baylin SB, Strick R. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. *Cell*. 2017;169(2):361.

24. Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. *Proc Natl Acad Sci U S A*. 2017;114(51):E10981- E10990.

25. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, O'Brien C, De Carvalho DD. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. *Cell*. 2015;162(5):961-973.

26. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. *Proc Natl Acad Sci U S A*. 1994;91(25):11797-11801.

27. Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekstrom TJ, Zhivotovsky B, Hellstrom-Lindberg E. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. *Exp Hematol*. 2008;36(2):149-157.

28. Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, Solomon LR, Boghaert ER, Leverson JD, Phillips DC. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. *Clin Cancer Res*. 2020;26(13):3371-3383.

29. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5- Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. *Leukemia*. 2014;28(8):1657-1665.

30. Lee TT, Karon MR. Inhibition of protein synthesis in 5-azacytidine-treated HeLa cells. *Biochem Pharmacol*. 1976;25(15):1737-1742.

31. Lu LJ, Randerath K. Mechanism of 5-azacytidine-induced transfer RNA cytosine-5 methyltransferase deficiency. *Cancer Res*. 1980;40(8 Pt 1):2701-2705.

32. Diesch J, Zwick A, Garz AK, Palau A, Buschbeck M, Gotze KS. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. *Clin Epigenetics*. 2016;8:71.

33. Awada H, Mahfouz RZ, Kishtagari A, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, Maciejewski JP, Saunthararajah Y. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *Br J Haematol*. 2020;188(6):924-929.

34. Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, Przychodzen B, Rump M, Hobson S, Earl M, Sobecks R, Dean R, Reu F, Tiu R, Hamilton B, Copelan E, Lichtin A, Hsi E, Kalaycio M, Maciejewski J. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. *J Clin Invest*. 2015;125(3):1043-1055.

35. Ali A, Penneroux J, Dal Bello R, Jr., Masse A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Ades L, Puissant A, Itzykson R. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. *Leukemia*. 2018;32(8):1856-1860.

36. Schnegg-Kaufmann AS, Thoms JAI, Bhuyan GS, Hampton HR, Vaughan L, Rutherford K, Kakadia PM, Lee HM, Johansson EMV, Failes TW, Arndt GM, Koval J, Lindeman R, Warburton P, Rodriguez-Meira A, Mead AJ, Unnikrishnan A, Davidson S, Polizzotto MN, Hertzberg M, Papaemmanuil E, Bohlander SK, Faridani OR, Jolly CJ, Zanini F, Pimanda JE. Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy. *Blood*. 2023;141(11):1316-1321.

37. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. *Nat Commun*. 2016;7:10767.

38. Kazachenka A, Young GR, Attig J, Kordella C, Lamprianidou E, Zoulia E, Vrachiolias G, Papoutselis M, Bernard E, Papaemmanuil E, Kotsianidis I, Kassiotis G. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression. *Genome Med*. 2019;11(1):86.

39. Kordella C, Lamprianidou E, Kotsianidis I. Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter. *Front Oncol*. 2021;11:650473.

40. Zavras PD, Shastri A, Goldfinger M, Verma AK, Saunthararajah Y. Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions. *Clin Cancer Res*. 2021;27(24):6653-6661.

41. Unnikrishnan A, Vo ANQ, Pickford R, Raftery MJ, Nunez AC, Verma A, Hesson LB, Pimanda JE. AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo. *Leukemia*. 2018;32(4):900-910.

42. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood*. 2006;108(2):419-425.

43. Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ades L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Diez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellstrom-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. *Blood*. 2023;141(17):2047-2061.

44. Rand KN, Molloy PL. Sensitive measurement of unmethylated repeat DNA sequences by endspecific PCR. *Biotechniques*. 2010;49(4):xiii-xvii.

45. Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, Ford KG, Mufti G. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. *Crit Rev Oncol Hematol*. 2013;88(2):231-245.

46. Subramanian S, Thoms JAI, Huang Y, Cornejo-Paramo P, Koch FC, Jacquelin S, Shen S, Song E, Joshi S, Brownlee C, Woll PS, Chacon-Fajardo D, Beck D, Curtis DJ, Yehson K, Antonenas V, O'Brien T, Trickett A, Powell JA, Lewis ID, Pitson SM, Gandhi MK, Lane SW, Vafaee F, Wong ES, Gottgens B, Alinejad-Rokny H, Wong JWH, Pimanda JE. Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs. *Blood*. 2023;142(17):1448-1462.

47. Thoms JAI, Koch FC, Raei A, Subramanian S, Wong JWH, Vafaee F, Pimanda JE. BloodChIP Xtra: an expanded database of comparative genome-wide transcription factor binding and gene-expression profiles in healthy human stem/progenitor subsets and leukemic cells. *Nucleic Acids Res*. 2024;52(D1):D1131-D1137.

48. Kumar D, Cinghu S, Oldfield AJ, Yang P, Jothi R. Decoding the function of bivalent chromatin in development and cancer. *Genome Res*. 2021;31(12):2170-2184.

49. Zhao W, Qiao L, Yan S, Nie Q, Zhang L. Mathematical modeling of histone modifications reveals the formation mechanism and function of bivalent chromatin. *iScience*. 2021;24(7):102732.

50. Horsfield JA. Full circle: a brief history of cohesin and the regulation of gene expression. *FEBS J*. 2023;290(7):1670-1687.

51. Rowley MJ, Corces VG. Organizational principles of 3D genome architecture. *Nat Rev Genet*. 2018;19(12):789-800.

52. Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martinez JS, Domenico D, Jadersten M, Germing U, Sanz G, van de Loosdrecht AA, Kosmider O, Follo MY, Thol F, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Ganster C, Ades L, Tobiasson M, Palomo L, Della Porta MG, Takaori-Kondo A, Ishikawa T, Chiba S, Kasahara S, Miyazaki Y, Viale A, Huberman K, Fenaux P, Belickova M, Savona MR, Klimek VM, Santos FPS, Boultwood J, Kotsianidis I, Santini V, Sole F, Platzbecker U, Heuser M, Valent P, Ohyashiki K, Finelli C, Voso MT, Shih LY, Fontenay M, Jansen JH, Cervera J, Gattermann N, Ebert BL, Bejar R, Malcovati L, Cazzola M, Ogawa S, Hellstrom-Lindberg E, Papaemmanuil E. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. *NEJM Evid*. 2022;1(7):EVIDoa2200008.

53. Bianchi A, Scherer M, Zaurin R, Quililan K, Velten L, Beekman R. scTAM-seq enables targeted high-confidence analysis of DNA methylation in single cells. *Genome Biol*. 2022;23(1):229.

54. Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini FM, Williams M, Fielding C, Fang Z, Khatib-Massalha E, Garcia-Garcia A, Li J, Khorshed RA, Gonzalez-Anton S, Baxter EJ, Kusumbe A, Wilkins BS, Green A, Simons BD, Harrison CN, Green AR, Lo Celso C, Theocharides APA, Mendez-Ferrer

S. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms. *Nat Cancer*. 2023;4(8):1193-1209.

55. Mendez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS. Bone marrow niches in haematological malignancies. *Nat Rev Cancer*. 2020;20(5):285- 298.

56. Mian SA, Bonnet D. Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes. *Cancers (Basel)*. 2021;13(16).

57. Poon Z, Dighe N, Venkatesan SS, Cheung AMS, Fan X, Bari S, Hota M, Ghosh S, Hwang WYK. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy. *Leukemia*. 2019;33(6):1487-1500.

58. Krueger F, James F, Ewels P, Afyounian E, Schuster-Boeckler BFJZhzor. TrimGalore: v0. 6.7. 2021.

59. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics*. 2011;27(11):1571-1572.

60. Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A, Mason CE. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. *Genome Biol*. 2012;13(10):R87.

61. Li S, Garrett-Bakelman FE, Akalin A, Zumbo P, Levine R, To BL, Lewis ID, Brown AL, D'Andrea RJ, Melnick A, Mason CE. An optimized algorithm for detecting and annotating regional differential methylation. *BMC Bioinformatics*. 2013;14 Suppl 5(Suppl 5):S10.

62. Yu G, Wang LG, He QY. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. *Bioinformatics*. 2015;31(14):2382-2383.

63. Cavalcante RG, Sartor MA. annotatr: genomic regions in context. *Bioinformatics*. 2017;33(15):2381-2383.

64. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS*. 2012;16(5):284-287.

65. Gel B, Diez-Villanueva A, Serra E, Buschbeck M, Peinado MA, Malinverni R. regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. *Bioinformatics*. 2016;32(2):289-291.

66. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from highthroughput sequencing data. *Nucleic Acids Res*. 2010;38(16):e164.

67. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. *Fly (Austin)*. 2012;6(2):80-92.

68. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, Alfoldi J, Watts NA, Vittal C, Gauthier LD, Poterba T, Wilson MW, Tarasova Y, Phu W, Grant R, Yohannes MT, Koenig Z, Farjoun Y, Banks E, Donnelly S, Gabriel S, Gupta N, Ferriera S, Tolonen C, Novod S, Bergelson L, Roazen D, Ruano-Rubio V, Covarrubias M, Llanwarne C, Petrillo N, Wade G, Jeandet T, Munshi R, Tibbetts K, Genome Aggregation Database C, O'Donnell-Luria A, Solomonson M, Seed C, Martin AR, Talkowski ME, Rehm HL, Daly MJ, Tiao G, Neale BM, MacArthur DG, Karczewski KJ. A genomic mutational constraint map using variation in 76,156 human genomes. *Nature*. 2024;625(7993):92-100.

69. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, Tukiainen T, Birnbaum DP, Kosmicki JA, Duncan LE, Estrada K, Zhao F, Zou J, Pierce-Hoffman E, Berghout J, Cooper DN, Deflaux N, DePristo M, Do R, Flannick J, Fromer M, Gauthier L, Goldstein J, Gupta N, Howrigan D, Kiezun A, Kurki MI, Moonshine AL, Natarajan P, Orozco L, Peloso GM, Poplin R, Rivas MA, Ruano-Rubio V, Rose SA, Ruderfer DM, Shakir K, Stenson PD, Stevens C, Thomas BP, Tiao G, Tusie-Luna MT, Weisburd B, Won HH, Yu D, Altshuler DM, Ardissino D, Boehnke M, Danesh J, Donnelly S, Elosua R, Florez JC, Gabriel SB, Getz G, Glatt SJ, Hultman CM, Kathiresan S, Laakso M, McCarroll S, McCarthy MI, McGovern D, McPherson R, Neale BM, Palotie A, Purcell SM, Saleheen D, Scharf JM, Sklar P, Sullivan PF, Tuomilehto J, Tsuang MT, Watkins HC, Wilson JG, Daly MJ,

MacArthur DG, Exome Aggregation C. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285-291.

70. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. *Nature*. 2015;526(7571):68-74.

Figure 2

Figure 3

Figure 4

Figure 6